Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

124.03

+0.49 (0.40%)

as of Jul 13, 2026, 8:00:00 pm Market Open.

311 watching

Investor Insights

Jul 13, 2026, 12:00 am

This summary was created by AI, based on 22 opinions in the last 12 months.

Merck & Company (MRK) is regarded as a strong investment opportunity, primarily due to its robust drug pipeline and significant growth potential despite challenges with its blockbuster drug, Keytruda, which is set to go off-patent in 2028. Analysts highlight the company's anticipated increase in sales, particularly from Keytruda and other new drugs in development. While some concerns exist regarding market fluctuations and pricing clarity, a substantial number of experts maintain an optimistic outlook on the stock's performance. With a promising array of drugs poised for release by 2030 and solid financial metrics, including rising cash reserves and share buybacks, MRK is projected to see continued growth, making it a compelling choice for healthcare investors. Expert recommendations suggest a prudent approach to stop-loss levels and target price adjustments.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfeizer, PFE

PAST TOP PICK

(A Top Pick Dec 03/18, Up 19%) This company's been on their top picks list since 2016. He spoke to the head of Research when they were brining forward immunotherapy drug Keytruda. The trials are going well over multiple trials. They are also #3 in the animal business too.

TOP PICK

His model price is $126 -- 41% potential upside. Demographics favour it. He can't understand why this sector is still so cheap. Yield 2.72% (Analysts’ price target is $99.24)

BUY

It's done quite well. New products are coming out. Dividend growth rate was 15% last year which is because of the new product cycle. Revenues were up by 12% which is big for the pharmaceutical sector.

BUY

Healthcare is a constructive space right now -- defensive, but not too expensive. MRK is a good candidate with a strong return on equity and fair valuation (17 times earnings) and debt is not an issue.

TOP PICK

Has done quite well relative to other healthcare names. Wide line of high marketing drugs, and a good pipeline of new drugs. One of the better names. 22 consecutive quarters of positive earnings. Decent PEG ratio. Yield is 2.66%. (Analysts’ price target is $96.29)

WAIT

If he had to pick one pharma, he'd pick Merck. Their pipeline is superior to peers, and well managed. But he wouldn't own the industry at this point in the cycle.

TOP PICK

Products marketed to over 140 countries. Main drugs in diabetes and oncology. Robust pipeline of new drugs, which will drive revenues over the long term. Not too expensive, with an 11-12% growth rate. Yield is 2.65%. (Analysts’ price target is $96.69)

BUY

Pfizer vs. Merck He owns both, which both score well in price momentum, high ROE, great balance sheet, pay a sustianble yield and are stable stocks. Merck has slightly better valuation metrics, but both stocks are very similar.

PAST TOP PICK

(A Top Pick Jul 05/18, Up 37%) It's been his top pick for three years. They continue to execute, like their immunotherapy drug. Trades at only 15x earnings with a good rate of return. The market is focused on their Keytruda therapy which merck is executing well.

TOP PICK

A diversified drugmaker that generates consistent returns. Patent declines are offset by a deep pipeline of new drugs from acquisitions. Also boast and organic R&D. MRK pays an attractive yield and has a decent balance sheet. Positive developments continue from Keytruda, an immuno-oncology therapy. MRK trades at 15x earnings. (Analysts’ price target is $91.73)

PAST TOP PICK

(A Top Pick Mar 21/18, Up 51%) Really likes it. A top pick for several years. Immunotherapy drug for cancer is leading the pack. Leader in the space.

PAST TOP PICK

(A Top Pick Apr 30/18, Up 44%) Likes healthcare. Chart is up and to the right. Any volatility has tended to be about politics. Secular bull market. Healthcare should be a core holding, and Merck would be a good place to start. Surgical devices like Baxter are also good.

DON'T BUY

Merck vs. Pfizer Two large pharma companies that are treading water. A lot of the drugs they develop are coming off patent. You must look at their pipelines, with Merck doing very well while Pfizer has some good franchises, like Lipitor. Merck likely has the better pipeline. Neither has enough revenue growth or cash flow to entice him to buy.

PAST TOP PICK

(A Top Pick Jul 05/18, Up 29%) An investor should diversify in the health sector, and MRK is a diversified health company. MRK has done very well in their oncology side. They're becoming dominant in immunotherapies. MRK gets their science and data right, unlike their peers.

TOP PICK

A long-time top pick. Their entire business line works, particularly immunotherapies. It's had a great run. He writes covered calls on this to generate extra income. (Analysts’ price target is $81.25)

Showing 121 to 135 of 305 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)